SCHEMBL753140

SCHEMBL753140

COC(=O)Cc1ccc(COc2ccc([C@@H](C)[C@@](O)(c3ccnc(Cl)c3)C(F)(F)F)c(Cl)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 1/20 0.44
CYP26A1 O43174 2/20 0.40
CYP3A4 P08684 2/20 0.40
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
FFAR1 O14842 3/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAOB P27338 2/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
SCN9A Q15858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479892 1.00 NPC1 (0.45) NPC1ALDH1A1RAB9ALMNACYP26A1
SCHEMBL753142 0.91 FFAR1 (0.42) CYP26A1CYP3A4NR1H2NR1H3FFAR1
SCHEMBL479814 0.91 FFAR1 (0.42) CYP26A1CYP3A4NR1H2NR1H3FFAR1
SCHEMBL479802 0.89 RXRA (0.45) NPC1RAB9ACYP26A1CYP3A4FFAR1
SCHEMBL752896 0.89 RXRA (0.45) NPC1RAB9ACYP26A1CYP3A4FFAR1
SCHEMBL754732 0.85 MAOB (0.45) ALDH1A1FFAR1SMN1; SMN2MAOB
SCHEMBL480004 0.85 MAOB (0.45) ALDH1A1FFAR1SMN1; SMN2MAOB
SCHEMBL752162 0.84 SMN1; SMN2 (0.46) NPC1ALDH1A1RAB9ALMNASMN1; SMN2
SCHEMBL479651 0.84 SMN1; SMN2 (0.46) NPC1ALDH1A1RAB9ALMNASMN1; SMN2
SCHEMBL15800836 0.83 LMNA (0.38) LMNAFFAR1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 NPC1 524/4885ALDH1A1 317/4885RAB9A 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.